0
0
India is on the brink of defining a regulatory framework for over-the-counter (OTC) drugs, a move that could revolutionize access to a range of medications. A subcommittee tasked with evaluating this shift is set to present its recommendations to the Drugs Technical Advisory Board (DTAB) in the coming days.
The move aims to allow certain prescription drugs to be sold directly to consumers without a prescription, thus making them more easily accessible in general stores. The government hopes this will streamline the availability of everyday medicines like cold remedies and contraceptives, which are already informally available but lack clear regulatory oversight.
Dr. Anupam Prakash, the chairman of the OTC subcommittee, confirmed that deliberations are ongoing and that the committee is weighing the most effective way to introduce this change. He explained that unlike countries such as the United States and the United Kingdom, India currently does not have a structured policy for OTC drug distribution, despite a significant demand for medicines that are commonly available without prescriptions.
The committee’s recommendations are expected to address concerns around ensuring the safe and responsible distribution of OTC drugs. One of the key challenges being considered is the regulation of antibiotics, with an emphasis on preventing misuse and overuse, which can lead to drug resistance. The committee is likely to propose amendments to the Drugs and Cosmetics Act to fill this regulatory gap.
As India moves towards finalizing the policy, the public will soon have access to a broader range of essential medicines over the counter. However, the government’s priority remains to balance ease of access with the safety and effectiveness of these medicines.
The final report will be submitted to the Drugs Technical Advisory Board, which will review the recommendations and determine the next steps for implementation. The expected policy change marks a significant step towards modernizing India’s healthcare system and enhancing the accessibility of vital medications.
(Source: Economic Times)
